摘要
目的检测肝癌患者血清聚腺苷酸二磷酸核糖聚合酶-1 (PARP-1)、半胱氨酸天冬氨酸蛋白酶-3(Caspase-3)蛋白表达水平,并探讨其在肝癌发生发展中的临床意义。方法收集2016年8月至2017年8月在盐城市大丰人民医院的65例肝癌患者以及25例健康体检者血清样本,应用酶联免疫吸附试验法检测血清中PARP-1、Caspase-3蛋白水平,并分析肝癌患者血清PARP-1、Caspase-3蛋白水平与临床特征的相关性及对患者生存期的影响。结果与健康人相比,肝癌患者血清PARP-1蛋白水平明显升高[(407±139) pg/mL vs (246±123) pg/mL],血清Caspase-3蛋白水平明显降低[(7.31±2.49) pg/mL vs (10.28±2.37) pg/mL],差异均有统计学意义(P<0.05);在有转移、饮酒史和乙肝表面抗原(HBsAg)阳性的肝癌患者中,血清PARP-1蛋白水平明显升高,差异均有统计学意义(P<0.05);在有转移和HBsAg阳性的肝癌患者中,血清Caspase-3蛋白水平明显降低,差异均有统计学意义(P<0.05);与血清PARP-1蛋白阴性的患者相比,PARP-1蛋白阳性的肝癌患者的总体生存期明显缩短[(18.5±6.3)个月vs (9.6±5.7)个月],差异有统计学意义(P<0.05);与血清Caspase-3蛋白阳性的患者相比,Caspase-3蛋白阴性的肝癌患者的总体生存期明显缩短[(17.9±6.5)个月vs (10.8±4.2)个月],差异有统计学意义(P<0.05);肝癌患者血清PARP-1与Caspase-3蛋白水平表达呈负相关(r=-0.369,P<0.05)。结论 PARP-1和Caspase-3在肝癌的发生、发展过程中起着重要作用,两者联合检测对肝癌的早期诊断具有一定价值。
Objective To explore the clinical significance of serum level of poly （ADP-ribose） polymerase-1 （PARP-1）, Caspase-3 protein in the onset and progression of hepatocellular carcinoma. Methods A total of 65 serum samples from hepatocellular carcinoma patients and 25 healthy subjects were collected in the People＇s Hospital of Yancheng from August 2016 to August 2017. The serum PARP-1, Caspase-3 protein levels were detected using en- zyme-linked immunosorbent assay method. The correlation of serum PARP-1, Caspase-3 protein levels with clinical characteristics of hepatocellular carcinoma and cancer-free survival was analyzed. Results Compared with health people, serum PARP-1 protein levels were significantly higher in hepatocellular carcinoma patients： （407±139） pg/mL vs （246±123） pg/mL （P〈0.05）, while serum Caspase-3 protein levels were significantly lower in hepatocellular carcinoma patients： （7.31±2.49） pg/mL vs （10.28±2.37） pg/mL （P〈0.05）. Serum PARP-1 protein levels in hepatocellular carcinoma patients with metastasis, alcohol intake history and HBsAg were significantly higher than those without metastasis, alcohol intake history and HBsAg （P〈0.05）, while serum Caspase-3 protein levels in hepatocellular carcinoma patients with metastasis and HBsAg were significantly lower. Compared with serum protein PARP-1 negative patients, PARP-1 protein positive patients had a significantly shorter cancer-free survival： （18.5±6.3） months vs （9.6±5.7） months （P〈0.05）. Compared with serum protein Caspase-3 positive patients, Caspase-3 protein negative patients had a significantly shorter cancer-free survival： （17.9±6.5） months vs （10.8±4.2） months （P〈0.05）. There was a negative correlation between serum PARP-1 protein levels and serum Caspase-3 protein levels in hepatocellular carcinoma patients （r=-0.369, P〈0.05）. Conclusion Both PARP-1 and Caspase-3 may be involved in the pathogenesis and progression of hepatocellular carcinoma. Combi
作者
胡顺明
王笑秋
邰少丽
李晓霞
HU Shun-ruing;WANG Xiao-qiu;TAI Shao-li;LI Xiao-xia(Department of Gastroenterology 1 Department of Clinical Laboratory;the People＇s Hospital of Yancheng,Yancheng 224100,Jiangsu,CHINA)
出处
《海南医学》
CAS
2018年第21期3021-3024,共4页
Hainan Medical Journal
